XTX Topco Ltd Cuts Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

XTX Topco Ltd lowered its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 56.6% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 11,623 shares of the biopharmaceutical company's stock after selling 15,179 shares during the period. XTX Topco Ltd's holdings in Catalyst Pharmaceuticals were worth $282,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Castlekeep Investment Advisors LLC bought a new position in Catalyst Pharmaceuticals in the fourth quarter valued at about $37,494,000. Bank of America Corp DE lifted its holdings in Catalyst Pharmaceuticals by 139.5% in the fourth quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company's stock valued at $32,741,000 after acquiring an additional 913,843 shares during the period. Allianz Asset Management GmbH lifted its holdings in Catalyst Pharmaceuticals by 397.8% in the first quarter. Allianz Asset Management GmbH now owns 694,125 shares of the biopharmaceutical company's stock valued at $16,833,000 after acquiring an additional 554,674 shares during the period. Raymond James Financial Inc. bought a new position in Catalyst Pharmaceuticals in the fourth quarter valued at about $6,887,000. Finally, JPMorgan Chase & Co. raised its holdings in Catalyst Pharmaceuticals by 80.3% in the 4th quarter. JPMorgan Chase & Co. now owns 736,197 shares of the biopharmaceutical company's stock worth $15,364,000 after purchasing an additional 327,936 shares during the period. Institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Up 3.4%

NASDAQ:CPRX traded up $0.66 during midday trading on Tuesday, hitting $20.34. The stock had a trading volume of 1,136,000 shares, compared to its average volume of 1,467,570. Catalyst Pharmaceuticals, Inc. has a one year low of $19.00 and a one year high of $26.58. The stock has a 50-day moving average of $22.07 and a 200 day moving average of $22.75. The company has a market capitalization of $2.49 billion, a price-to-earnings ratio of 12.33, a PEG ratio of 0.80 and a beta of 0.70.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Wall Street Zen cut Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Saturday. One research analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $33.20.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 1,600 shares of the stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total transaction of $42,272.00. Following the completion of the sale, the insider directly owned 41,081 shares of the company's stock, valued at approximately $1,085,360.02. This represents a 3.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Gary Ingenito sold 44,000 shares of the stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total value of $1,039,720.00. Following the completion of the sale, the insider owned 68,873 shares of the company's stock, valued at approximately $1,627,468.99. This trade represents a 38.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,924 shares of company stock valued at $1,143,369 in the last ninety days. Corporate insiders own 10.40% of the company's stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.